Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Thrombosis and Haemostasis Année : 2021

Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study

Aby Abraham
  • Fonction : Auteur
Leonid Dubey
  • Fonction : Auteur
Yves Gruel
Sunil Lohade
  • Fonction : Auteur
Berardino Pollio
  • Fonction : Auteur
Vladimir Vdovin
  • Fonction : Auteur
Kateryna Vilchevska
  • Fonction : Auteur
Martina Jansen
  • Fonction : Auteur
Larisa Belyanskaya
  • Fonction : Auteur
Olaf Walter
  • Fonction : Auteur
Sigurd Knaub
  • Fonction : Auteur

Résumé

Introduction FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly in previously untreated patients (PUPs). No inhibitors developed in clinical trials in previously treated patients treated with simoctocog alfa (Nuwiq), a fourth-generation recombinant FVIII produced in a human cell line. Methods The NuProtect study investigated the immunogenicity of simoctocog alfa in PUPs. NuProtect was a prospective, multinational, open-label, non-controlled, phase III study. PUPs with severe haemophilia A (FVIII:C <1%) of any age and ethnicity were treated with simoctocog alfa for 100 exposure days or a maximum of 5 years. Patients were true PUPs without prior exposure to FVIII concentrates or blood components. Inhibitor titres were measured with the Nijmegen-modified Bethesda assay; cut-off for positivity was 0.6 BU mL (-1) (<greater than or equal to>0.6 to <5 low-titre, <greater than or equal to>5 high titre). Results A total of 108 PUPs with a median age at first treatment of 12.0 months (interquartile range: 8.0-23.5) were treated with simoctocog alfa. F8 mutation type was known for 102 patients (94.4%) of whom 90 (88.2%) had null F8 mutations and 12 (11.8%) had non-null mutations. Of 105 PUPs evaluable for inhibitor development, 28 (26.7%) developed inhibitors; 17 high titre (16.2%) and 11 low titre (10.5%). No PUPs with non-null F8 mutations developed inhibitors. Conclusion In the NuProtect study, the rate of inhibitor development in PUPs with severe haemophilia A treated with simoctocog alfa was lower than the rate reported for hamster-cell-derived recombinant factor VIII products in other recent clinical trials. No inhibitors were reported in PUPs with non-null F8 mutations.

Domaines

Hématologie
Fichier principal
Vignette du fichier
s-0040-1722623.pdf (399.49 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03162369 , version 1 (08-03-2021)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Ri J. Liesner, Aby Abraham, Carmen Altisent, Mark J. Belletrutti, Manuel Carcao, et al.. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis, 2021, 121 (11), pp.1400-1408. ⟨10.1055/s-0040-1722623⟩. ⟨hal-03162369⟩
113 Consultations
141 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More